Literature DB >> 17226843

Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses.

Florian Ertle1, Wolfgang Behnisch, Naima Ali Al Mulla, Mohammed Bessisso, Dietz Rating, Gunhild Mechtersheimer, Barbara Hero, Andreas E Kulozik.   

Abstract

Opsoclonus-myoclonus-ataxia-syndrome (OMS) represents a rare neuroblastoma-associated paraneoplastic syndrome that commonly results in neurologic deficits despite tumor resection and immunosuppressive therapy. We describe the response of five such children to high-dose dexamethasone pulses including two patients in whom previous glucocorticoids, rituximab, and cytostatic drugs were not successful. All patients had MYCN non-amplified tumors that were detected 1 to 7 months after the onset of the OMS or ataxia. This treatment resulted in a good partial response in three and in complete remission in two patients. Our results show that dexamethasone pulses are likely to be useful for both, first-line- and salvage-therapy for OMS-patients. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17226843     DOI: 10.1002/pbc.21107

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Paraneoplastic neurologic disorders in children.

Authors:  Elizabeth M Wells; Josep Dalmau
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

Review 2.  Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Authors:  Henrik Gensicke; David Leppert; Özgür Yaldizli; Raija L P Lindberg; Matthias Mehling; Ludwig Kappos; Jens Kuhle
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

3.  Paraneoplastic brain stem encephalitis.

Authors:  Franz Blaes
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

Review 4.  Paraneoplastic neurologic syndromes in children: a review article.

Authors:  Samin Alavi
Journal:  Iran J Child Neurol       Date:  2013

5.  Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee
Journal:  Front Neurol       Date:  2017-09-11       Impact factor: 4.003

Review 6.  Update on opsoclonus-myoclonus syndrome in adults.

Authors:  Sun-Young Oh; Ji-Soo Kim; Marianne Dieterich
Journal:  J Neurol       Date:  2018-11-27       Impact factor: 4.849

7.  Clinical responses to rituximab in a case of neuroblastoma with refractory opsoclonus myoclonus ataxia syndrome.

Authors:  Samin Alavi; Ali Kord Valeshabad; Borhan Moradveisi; Ali Aminasnafi; Mohammad Taghi Arzanian
Journal:  Case Rep Oncol Med       Date:  2012-11-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.